Background: The complex nature of musculoskeletal diseases and the limitations of existing treatments have driven researchers to explore innovative solutions, particularly those involving stem cells and their derivatives. The utilization of the IPFP as a source of MSC-derived non-cellular products for the treatment of musculoskeletal diseases has gained recognition in recent years. This study aimed to identify the progress of IPFP-derived acellular biologics use in the treatment of orthopedic conditions such as osteoarthritis and ligament and/or tendon injuries.
Methods: A literature search was conducted through PubMed, Scopus and Google Scholar databases including studies over the past 10 years. This scoping review includes studies discussing the development of intercellular messenger signaling molecules (non-cellular products) in the form of exosomes, secretomes, and conditioned medium derived from the IPFP in the management of musculoskeletal diseases. The PRISMA-ScR guidelines were utilized in this review.
Results: Six studies met the inclusion criteria. Most studies reported the beneficial anti-inflammatory effects of IPFP-derived noncellular products in musculoskeletal conditions. The effects of IPFP-derived exosomes, secretomes, and conditioned medium administration are mostly reported in microscopic changes through cellular and matrix changes. Additionally, quantitative analyses involved assessing levels of anti-inflammatory and pro-inflammatory markers, proteins, fatty acids, and gene expression.
Conclusions: The use of IPFP-derived non-cellular products has shown significant promise in the regenerative therapy for musculoskeletal diseases. These agents have demonstrated beneficial effects, particularly in reducing inflammation, promoting cellular changes, and enhancing tissue regeneration. However, further research is needed to fully understand the characteristics and explore the potential applications of IPFP-derived non-cellular products in musculoskeletal cases.